Ionis and AstraZeneca to develop and commercialize eplontersen
- Tuesday, December 7, 2021, 2:19
- PR Newswire
- Add a comment
CARLSBAD, Calif., Dec. 7, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational…
About the Author
admin has written 20663 stories on this site.